Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas

References

• Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumors of haematopoietic and lymphoid tissues. 3rd ed. Lyon, France: IARC Press; 2001.
   Google Scholar
• Gribben JG. How I treat indolent lymphoma. Blood 2007;109: 4617–4626.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Abramson JS, Advani RH, et al. Non-Hodgkin's lymphomas. J Natl Comp Canc Netw 2011;9:484–560.
   PubMed Web of Science ®Google Scholar
• Bollosillo B, Villamour N, Colomer D, et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukaemia. Blood 1999;94:2836–2843.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Nowak BJ, Keating MJ, et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001;7:3580–3589.
   PubMed Web of Science ®Google Scholar
• Hochster HS, Oken MM, Winter JN, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow- up–a report from the Eastern Cooperative Oncology Group. J Clin Oncol 2000;18:987–994.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007;25:793–798.
   PubMed Web of Science ®Google Scholar
• Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. Hematol J 2004;5:472–474.
   PubMedGoogle Scholar
• Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Forconi F, Fabbri A, Lenoci M, et al. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. Hematol Oncol 2008;26:247–251.
   PubMed Web of Science ®Google Scholar
• Ferrario A, Merli F, Luminari S, et al. Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Ann Hematol 2011;90:323–330.
   PubMed Web of Science ®Google Scholar
• Cartron G, Trappe RU, Solal-Céligny P, et al. Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 2011;17:9–30.
   Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28: 1756–1765.
   PubMed Web of Science ®Google Scholar
• Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23: 4070–4078.
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–980.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Ferrario A, Pulsoni A, Olivero B, et al. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation. Cancer 2012;118:3954–3961.
   PubMed Web of Science ®Google Scholar
• Frewin R, Turner D, Tighe M, et al. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol 1999;104:612–613.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001;19:1414–1420.
   PubMed Web of Science ®Google Scholar
• Shvidel L, Shtalrid M, Bairey O, et al. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma 2003;44:1947–1950.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Tam CS, Wolf MM, Januszewicz EH, et al. Fludarabine and cyclophosphamide using an attenuated dose schedule is highly effective regimen for patients with indolent lymphoid malignancies. Cancer 2004;100:2181–2189.
   PubMed Web of Science ®Google Scholar
• Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:498–503.
   PubMed Web of Science ®Google Scholar
• Boogaerts MA, Van Hoof A, Catovsky D, et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001;19:4252–4258.
   PubMed Web of Science ®Google Scholar
• Tobinai K, Watanabe T, Ogura M, et al. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2006;24:174–180.
   PubMed Web of Science ®Google Scholar
• Dearden CE, Richards S, Else M, et al. A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial. Cancer 2010 Dec 14. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Laurenti L, De Padua L, Tarnani M, et al. Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome. Ann Hematol 2011;90:59–65.
   PubMed Web of Science ®Google Scholar
• Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. Br J Haematol 2007;139: 90–93.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244–1253.
   Web of Science ®Google Scholar
• Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   Google Scholar
• Shustik C, Turner AR, Desjardins L, et al. Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2010;24:237–239.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet 2011;377:42–51.
   PubMed Web of Science ®Google Scholar